Iatrogenic adrenal insufficiency secondary to an interaction between ritonavir and inhaled fluticasone. A review of the literature
Copyright © 2013 Elsevier España, S.L.U. y Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. All rights reserved..
INTRODUCTION: Highly effective antiretroviral treatment has improved the life expectancy of human immunodeficiency virus (HIV) infected patients, but has led to an increase in the comorbidities related to aging, such as the chronic obstructive pulmonary disease (COPD). All this implies the need for a greater number of drugs and an increasing risk of drugs interactions with antiretroviral treatment, particularly protease inhibitors.
METHODS: We report a case of iatrogenic adrenal insufficiency interaction secondary to ritonavir and inhaled fluticasone in an HIV-infected patient with COPD. A review was made of the cases reported in adults in the medical literature (Medline) up to December 2012.
RESULTS: A total of 34 cases were reported. The mean age was 4 years. The mean dose of ritonavir was 187 mg/day, while the fluticasone dose was 866 μg/day. The average time of the interaction between ritonavir and fluticasone was 8 months. In 85% of cases fluticasone was discontinued at the time of diagnosis of adrenal insufficiency/Cushing syndrome. Almost all (90%) patients had a complete resolution of the symptoms after changing the treatment.
CONCLUSION: HIV-infected patients on antiretroviral therapy with protease inhibitor boosted with ritonavir which requires the use of inhaled corticosteroids, beclomethasone would be the best treatment option.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2014 |
|---|---|
| Erschienen: |
2014 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:32 |
|---|---|
| Enthalten in: |
Enfermedades infecciosas y microbiologia clinica - 32(2014), 10 vom: 06. Dez., Seite 662-5 |
| Sprache: |
Spanisch |
|---|
| Weiterer Titel: |
Insuficiencia suprarrenal iatrogénica por la interacción entre ritonavir y fluticasona inhalada. Revisión de la literatura |
|---|
| Beteiligte Personen: |
Gómez-Cerquera, Juan Manuel [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adrenal insufficiency |
|---|
| Anmerkungen: |
Date Completed 12.01.2017 Date Revised 13.01.2017 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.eimc.2013.12.008 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM235468320 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM235468320 | ||
| 003 | DE-627 | ||
| 005 | 20231224103454.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2014 xx |||||o 00| ||spa c | ||
| 024 | 7 | |a 10.1016/j.eimc.2013.12.008 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0785.xml |
| 035 | |a (DE-627)NLM235468320 | ||
| 035 | |a (NLM)24529679 | ||
| 035 | |a (PII)S0213-005X(14)00007-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a spa | ||
| 100 | 1 | |a Gómez-Cerquera, Juan Manuel |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Iatrogenic adrenal insufficiency secondary to an interaction between ritonavir and inhaled fluticasone. A review of the literature |
| 246 | 3 | 3 | |a Insuficiencia suprarrenal iatrogénica por la interacción entre ritonavir y fluticasona inhalada. Revisión de la literatura |
| 264 | 1 | |c 2014 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.01.2017 | ||
| 500 | |a Date Revised 13.01.2017 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2013 Elsevier España, S.L.U. y Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. All rights reserved. | ||
| 520 | |a INTRODUCTION: Highly effective antiretroviral treatment has improved the life expectancy of human immunodeficiency virus (HIV) infected patients, but has led to an increase in the comorbidities related to aging, such as the chronic obstructive pulmonary disease (COPD). All this implies the need for a greater number of drugs and an increasing risk of drugs interactions with antiretroviral treatment, particularly protease inhibitors | ||
| 520 | |a METHODS: We report a case of iatrogenic adrenal insufficiency interaction secondary to ritonavir and inhaled fluticasone in an HIV-infected patient with COPD. A review was made of the cases reported in adults in the medical literature (Medline) up to December 2012 | ||
| 520 | |a RESULTS: A total of 34 cases were reported. The mean age was 4 years. The mean dose of ritonavir was 187 mg/day, while the fluticasone dose was 866 μg/day. The average time of the interaction between ritonavir and fluticasone was 8 months. In 85% of cases fluticasone was discontinued at the time of diagnosis of adrenal insufficiency/Cushing syndrome. Almost all (90%) patients had a complete resolution of the symptoms after changing the treatment | ||
| 520 | |a CONCLUSION: HIV-infected patients on antiretroviral therapy with protease inhibitor boosted with ritonavir which requires the use of inhaled corticosteroids, beclomethasone would be the best treatment option | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Adrenal insufficiency | |
| 650 | 4 | |a Cushing | |
| 650 | 4 | |a Fluticasona | |
| 650 | 4 | |a Fluticasone | |
| 650 | 4 | |a Insuficiencia suprarrenal | |
| 650 | 4 | |a Ritonavir | |
| 650 | 7 | |a Bronchodilator Agents |2 NLM | |
| 650 | 7 | |a HIV Protease Inhibitors |2 NLM | |
| 650 | 7 | |a Fluticasone |2 NLM | |
| 650 | 7 | |a CUT2W21N7U |2 NLM | |
| 650 | 7 | |a Ritonavir |2 NLM | |
| 650 | 7 | |a O3J8G9O825 |2 NLM | |
| 700 | 1 | |a Hernando-López, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Blanco-Ramos, José Ramón |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Enfermedades infecciosas y microbiologia clinica |d 1993 |g 32(2014), 10 vom: 06. Dez., Seite 662-5 |w (DE-627)NLM01273425X |x 1578-1852 |7 nnns |
| 773 | 1 | 8 | |g volume:32 |g year:2014 |g number:10 |g day:06 |g month:12 |g pages:662-5 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.eimc.2013.12.008 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 32 |j 2014 |e 10 |b 06 |c 12 |h 662-5 | ||